Case Report: Neoadjuvant and Adjuvant Crizotinib Targeted Therapy in Stage IIIA-N2 ALK-Positive Non-Small-Cell Lung Cancer

Case report of systemic treatment with ALK inhibitor crizotinib before surgery showing it may provide the potential to cure the initially inoperable tumor. READ ARTICLE

Frontiers in Oncology DOI:10.3389/fonc.2021.655856

Authors: Xiao-Hong Xie, Ze-Jiang Zhan, Yin-Yin Qin, Ju-Hong Jiang, Wei-Qiang Yin, Rong-Hui Zheng, Shi-Yue Li, Cheng-Zhi Zhou